Compare · GKOS vs SYK
GKOS vs SYK
Side-by-side comparison of Glaukos Corporation (GKOS) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GKOS and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $126.81B, about 11.9x GKOS ($10.70B).
- Over the past year, GKOS is up 93.4% and SYK is down 16.2% - GKOS leads by 109.6 points.
- SYK has been more active in the news (9 items in the past 4 weeks vs 6 for GKOS).
- Both have 25 recent analyst ratings on file.
- Company
- Glaukos Corporation
- Stryker Corporation
- Price
- $181.35-2.36%
- $330.59+0.86%
- Market cap
- $10.70B
- $126.81B
- 1M return
- +19.27%
- -1.81%
- 1Y return
- +93.37%
- -16.24%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2015
- News (4w)
- 6
- 9
- Recent ratings
- 25
- 25
Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest GKOS
- Director Kliman Gilbert H exercised 2,500 shares at a strike of $25.77 and sold $475,000 worth of shares (2,500 units at $190.00) (SEC Form 4)
- Glaukos Announces Participation in Wells Fargo Healthcare Conference
- PRESIDENT & COO Gilliam Joseph E sold $10,784,659 worth of shares (60,000 units at $179.74) and exercised 60,000 shares at a strike of $52.94 (SEC Form 4)
- SVP & CHIEF FINANCIAL OFFICER Thurman Alex R. sold $3,602,600 worth of shares (20,000 units at $180.13) as part of a pre-agreed trading plan and exercised 20,000 shares at a strike of $33.81 (SEC Form 4)
- Director Wen Leana sold $88,006 worth of shares (525 units at $167.63), decreasing direct ownership by 2% to 21,092 units (SEC Form 4)
- Glaukos Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Glaukos Corporation
- Glaukos Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Glaukos Announces Second Quarter 2026 Financial Results
- UBS initiated coverage on Glaukos
Latest SYK
- Director Stryker Ronda E sold $117,776,128 worth of shares (350,000 units at $336.50) (SEC Form 4)
- Officer King Debra sold $277,787 worth of shares (826 units at $336.30), decreasing direct ownership by 12% to 6,210 units (SEC Form 4)
- Stryker downgraded by Wolfe Research
- Providence™ Medical Technology Appoints Lane Major as President & Chief Executive Officer
- Stryker declares an $0.88 per share quarterly dividend
- VP, Chief Comm. Officer Montagnino Kimberly Ann covered exercise/tax liability with 155 shares, decreasing direct ownership by 8% to 1,717 units (SEC Form 4)
- Officer King Debra covered exercise/tax liability with 533 shares, decreasing direct ownership by 7% to 7,036 units (SEC Form 4)
- VP, Chief Legal Officer Fletcher Robert S covered exercise/tax liability with 94 shares, decreasing direct ownership by 0.89% to 10,488 units (SEC Form 4)
- VP, Chief HR Officer Fink M Kathryn covered exercise/tax liability with 111 shares, decreasing direct ownership by 0.84% to 13,027 units (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation